Publications by authors named "G Hazlewood"
Background: Allogeneic bone marrow transplantation (BMT) may be a curative treatment for patients with rheumatoid arthritis (RA), but it has serious risks, including death. It is uncertain whether patients would accept the risks and benefits of BMT and participate in clinical trials. We conducted a discrete choice experiment (DCE) to quantify risk tolerance and benefit-risk trade-offs to inform the design of a clinical trial for BMT.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to understand nonarticular pain (NAP) in patients newly diagnosed with rheumatoid arthritis (RA), tracking its changes during the first year of treatment and linking it with active inflammation and remission outcomes.
- More than half of the participants (392, mostly female, average age of 56) experienced NAP, with the majority reporting regional pain, which often persisted or worsened over time.
- The results indicated that both regional and widespread NAP were negatively associated with achieving remission, suggesting that addressing NAP is crucial in managing early RA.
Clinical Question: In adult patients with inflammatory bowel disease, inflammatory arthritis (rheumatoid arthritis, spondyloarthritis, psoriatic arthritis), or psoriasis taking biologic drugs, does proactive therapeutic drug monitoring (TDM) improve outcomes as compared with standard care?
Context And Current Practice: Standard care for immune mediated inflammatory diseases includes prescribing biologic drugs at pre-determined doses. Dosing may be adjusted reactively, for example with increased disease activity. In proactive TDM, serum drug levels and anti-drug antibodies are measured irrespective of disease activity, and the drug dosing is adjusted to achieve target serum drug levels, usually within pre-specified therapeutic ranges.